Skip to main content
OpenTrials
Completed

NCT Number: NCT04040296

Personalized Recommendations for Acute Kidney Injury (AKI) Care

This is a randomized clinical trial of a "Kidney Action Team", which will provide timely, personalized recommendations for the diagnosis and initial treatment of hospitalized patients with Acute Kidney Injury (AKI).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Yale New Haven Hospital

New Haven, Connecticut, 06510, United States

About this study

Acute Kidney Injury (AKI), defined as an abrupt loss in kidney function, is common, occurring in 5-20% of hospitalized patients, and carries a significant and independent risk of inpatient mortality. International guidelines for the treatment of AKI focus on "best practices" that include appropriate management of drug dosing, the avoidance of kidney-toxic exposures, and careful assessment of fluid and electrolyte balance. Early nephrologist involvement may also improve outcomes in AKI. However, AKI, which is often asymptomatic, is frequently overlooked in a variety of hospital settings and many "best practices" occur infrequently and inconsistently.

The investigators previously conducted a randomized clinical trial testing the efficacy of electronic alerts for AKI, randomizing patients with AKI to usual care, or to an alert group in which a single alert was sent to the patient's primary provider. The study demonstrated clinical equipoise regarding the effectiveness of such alerting, as there was no improvement in the rates of AKI progression, dialysis or mortality among those in the alert group.

Rather than simply making providers aware of AKI, it may be beneficial to provide them with actionable items to increase recognition and rate of best practices. Further, because of the heterogeneous nature of AKI, personalized recommendations tailored to individual patients that are delivered directly to the patient care team may improve AKI outcomes. The aim of this study is to determine, through a single-blind, parallel group, randomized controlled multicenter clinical trial, if personalized recommendations, as delivered by a Kidney Action Team, for the work-up and treatment of AKI will improve patient outcomes. The Kidney Action team will serve as a centralized, remote monitoring service and will consist of a group of highly trained individuals, including an advanced practitioner, a pharmacist and a board-certified nephrologist, dedicated to reviewing enrolled patient's charts and providing recommendations for patient diagnosis and initial work up and care within 60 minutes of AKI onset. Recommendations will span five domains of care, including diagnostic workup, acid/base management, electrolyte management, hemodynamic management, and medication management.

Using the Kidney Disease: Improve Global Outcomes creatinine criteria, inpatients in sites of the Yale New Haven Health System and of the John Hopkins University Health System who develop AKI during the course of their hospitalization will be randomized to either receive usual care, or to an active intervention group in which the recommendations of the Kidney Action Team are delivered to the patient's primary care team in the form of a structured note in the electronic health record to be cosigned by the attending of record. The primary clinical outcome will be a composite of AKI progression, dialysis and death at 14 days post-randomization. The primary process outcome will be the percent of recommendations made that are enacted within 24 hours after randomization.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults ≥ 18 years admitted to a participating hospital (six hospitals in the Yale New Haven Health system and two hospitals of the John Hopkins University Health system)
  • Stage 1 Acute Kidney Injury as defined by KDIGO creatinine criteria:
  • 0.3 mg/dl increase in inpatient serum creatine over 48 hours OR
  • 50% relative increase in inpatient serum creatinine over 168 hours

Exclusion criteria

  • Admission to hospice service or comfort measures only order
  • Recipient of a solid organ transplant
  • Immediate dialytic indication determined by the following:
  • serum K >/= 7
  • arterial pH < 7.15
  • BUN > 150 mg/dL
  • acute ingestion of dialyzable toxins
  • refractory volume overload

Patients who meet any of these critical values will not be enrolled in the trial and the Kidney Action Team will directly notify the treating team.

  • Pre-existing CKD stage V or End Stage Kidney Disease
  • Initial hospital creatinine > 4.0 mg/dl
  • Patients who have been seen by nephrology or already have a nephrology consult
  • Status post-nephrectomy (partial or radical) during index admission

Treatment and study plan

Kidney Action Team Recommendations

Other

Upon review of the patient's medical information, the Kidney Action Team will create personalized recommendations that will be delivered to the patient's primary care team via a specialized note in the electronic medical record system within 2 hours of AKI detection. The attending of record will be identified as a cosigner to ensure that a member of the care team is made aware of the note's presence.

Primary outcomes

  1. Composite Outcome Showing the Percentage of Participants With Any One of the Following: Progression of AKI, Inpatient Dialysis, or Inpatient Death

    Time frame: 14 days post randomization or at hospital discharge, whichever comes first

    Progression of AKI is defined by an increase in KDIGO creatinine stage from that present at the time of randomization.

    Dialysis is defined by the receipt of hemodialysis, continuous renal replacement therapy or peritoneal dialysis. Isolated ultrafiltration treatments (for the purpose of volume removal) will not be included.

    Mortality will be determined from hospital administrative records.

    The rates of the primary outcome will be compared between the study arms using the Cochrane-Mantel-Haenszel chi-square test, accounting for stratification by hospital.

Secondary outcomes

  1. Percentage of Recommendations Implemented by the Primary Care Team

    Time frame: 24 hours after randomization

    The AKI Response Team will make recommendations for all randomized patients in both the control group and the intervention group, however, recommendations will only be delivered to the primary care teams of patients in the intervention group. In this way, we can compare the percentage of recommendations that were followed by primary care teams across both groups. This outcome will be assessed by averaging the proportion of recommendations followed within 24 hours between the two study arms using the Van Elteren test to account for stratification by hospital.

  2. Percentage of Patients With Progression of Acute Kidney Injury

    Time frame: Assessed from time of randomization to time of AKI progression (within 14 days post randomization)

    Percentage of patients who progressed from stage 1 to stage 2 or 3 or from stage 2 to stage 3 (based on changes in creatinine) within 14 days of randomization

  3. Percentage of Patients Who Receive Inpatient Dialysis

    Time frame: Assessed from time of randomization to time of receipt of inpatient dialysis (within 14 days post randomization)

    Percentage of patients who receive hemodialysis, continuous renal replacement, or peritoneal dialysis during index hospitalization within 14 days of randomization

  4. Percentage of Inpatient Mortality

    Time frame: Assessed from time of randomization to date of death from any cause, within 14 days of randomization

    Proportion of patients who expire within 14 days of randomization

  5. Percent of Patients Who Receive a Kidney Consult Within 14 Days

    Time frame: Assessed from the time of randomization to time of first kidney consult (within 14 days post-randomization)

    Percent of participants receiving a kidney consult within 14 days of randomization

  6. Percent of Patients Who Are Discharged to Hospice Care 14 Days

    Time frame: Assessed from the time of randomization to time discharge to hospice (within 14 days post-randomization)

    Percent of participants discharged to hospice within 14 days of randomization

Sponsors and collaborators

Lead sponsor

Yale University

Other

Collaborators

  • Johns Hopkins University

Registry information

Official study title

Personalized Recommendations for Acute Kidney Injury (AKI) Care Using a Kidney Action Team: A Randomized Trial

Important dates

Study start
2021
Primary completion
2024
Study completion
2024
First posted
Jul 31, 2019
Registry last updated
Jul 17, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.